leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience bolsters board of directors with Al Reese Jr

Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company

Lexaria Bioscience Corp. -
"With the new capital and the right amount of capital discipline, Lexaria should have an excellent future," said Reese

Lexaria Bioscience Corp (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) has bolstered its board with the addition of Al Reese Jr. 

Certified accountant Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company, where he arranged transactions totaling more than US$10 billion over two decades. 

READ: Lexaria Bioscience prices $9.6M public offering as shares set to begin trading on the Nasdaq

"Al is also experienced in negotiating technology license agreements with companies in the US and internationally, and the board of directors looks forward to his guidance as Lexaria continues to evolve and pursue its strategic out-licensing business model," said Chris Bunka, CEO and chairman, at Lexaria.

Reese added in the statement: "I’ve been familiar with Lexaria since inception and have seen this team’s determination to develop and commercialize the DehydraTECH TM technology. 

"With the recent capital raise, Lexaria now has sufficient capital to conduct the studies and programs to continue to find new and expanded applications of DehydraTECH and other Lexaria opportunities.

"With the new capital and the right amount of capital discipline, Lexaria should have an excellent future. It is an honor to be part of it."

Also in the statement, the company updated on its application to the US National Institutes of Health (NIH) for a grant to support its second round of planned studies relating to treatment options for coronavirus (COVID-19), announced last summer, saying members of a review group had met to consider applications but Lexaria’s had not been discussed or scored.

"As such, it is not likely that Lexaria’s application will be funded relative to other applications they prioritized, although no definitive decision has yet been provided to Lexaria," the company noted.

Lexaria's proprietary drug delivery technology improves the way active pharmaceutical ingredients (APIs) enter the bloodstream and increases the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.

Shares in Canada nudged up 0.87% to C$5.83 each.

---Updates for share price---

Contact the author at giles@proactiveinvestors.com

Quick facts: Lexaria Bioscience Corp.

Price: 6.92 CAD

CSE:LXX
Market: CSE
Market Cap: $35.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

After successful raise of 11 million dollars, Lexaria Bioscience spells out...

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives. Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension...

on 02/01/2021

2 min read